期刊
BIOMATERIALS
卷 34, 期 4, 页码 1018-1023出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.10.050
关键词
Fungal keratitis; Main-chain polyimidazolium; Broad spectrum antimicrobial agent; Hemocompatible; Biofilm
资金
- Institute of Bioengineering and Nanotechnology (Biomedical Research Council, A*STAR)
- Exploit Technologies Pte Ltd (A*STAR)
Fungal keratitis is a leading cause of ocular morbidity throughout the world. However, current therapies against fungal keratitis are often ineffective. Herein, we have developed the amphiphilic main-chain imidazolium polymer (PIM-45) and oligomer (IBN-1) materials that can efficiently inhibit the growth of fungi with low minimal inhibition concentration (MIC) values and clear the fungal biofilm, while displaying minimal hemolysis. In vivo keratitis treatment indicates that topical solutions of these polyimidazolium salts (PIMSs) are safe and as effective as that of amphotericin B, the most commonly used agent for the treatment of Candida albicans (C albicans) keratitis. Compared to the costly and unstable amphotericin B and fluconazole, PIM-45 and IBN-1 are easy to prepare, inexpensive and stable. They can be stored in phosphate-buffered saline (PBS) solutions with long shelf life for routine topical use. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据